Optimization and Evaluation of 5‐Styryl‐Oxathiazol‐2‐one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents

This is the first report of 5‐styryl‐oxathiazol‐2‐ones as inhibitors of the Mycobacterium tuberculosis (Mtb) proteasome. As part of the study, the structure–activity relationship of oxathiazolones as Mtb proteasome inhibitors has been investigated. Furthermore, the prepared compounds displayed a goo...

Full description

Saved in:
Bibliographic Details
Published in:ChemistryOpen (Weinheim) 2015-06, Vol.4 (3), p.342-362
Main Authors: Russo, Francesco, Gising, Johan, Åkerbladh, Linda, Roos, Annette K., Naworyta, Agata, Mowbray, Sherry L., Sokolowski, Anders, Henderson, Ian, Alling, Torey, Bailey, Mai A., Files, Megan, Parish, Tanya, Karlén, Anders, Larhed, Mats
Format: Article
Language:English
Subjects:
5-styryl-oxathiazolones
antitubercular agents
Bacteria
Drugs
Human
Inhibitors
Mtb proteasome inhibitor
Mycobacterium tuberculosis
nonreplicating Mtb
Optimization
rapid bactericidal activity
Selectivity
Therapy
Tuberculosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This is the first report of 5‐styryl‐oxathiazol‐2‐ones as inhibitors of the Mycobacterium tuberculosis (Mtb) proteasome. As part of the study, the structure–activity relationship of oxathiazolones as Mtb proteasome inhibitors has been investigated. Furthermore, the prepared compounds displayed a good selectivity profile for Mtb compared to the human proteasome. The 5‐styryl‐oxathiazol‐2‐one inhibitors identified showed little activity against replicating Mtb, but were rapidly bactericidal against nonreplicating bacteria. (E)‐5‐(4‐Chlorostyryl)‐1,3,4‐oxathiazol‐2‐one) was most effective, reducing the colony‐forming units (CFU)/mL below the detection limit in only seven days at all concentrations tested. The results suggest that this new class of Mtb proteasome inhibitors has the potential to be further developed into novel antitubercular agents for synergistic combination therapies with existing drugs. Targeting tuberculosis: 5‐styryl‐oxathiazol‐2‐ones were found to be inhibitors of the Mycobacterium tuberculosis (Mtb) proteasome. The compounds displayed a good selectivity for Mtb and were rapidly bactericidal against nonreplicating Mtb. The results suggest that this new class of Mtb proteasome inhibitors has the potential to be further developed into novel antitubercular agents for synergistic combination therapies with existing drugs.
ISSN:2191-1363
2191-1363
DOI:10.1002/open.201500001